During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...

From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ...

NICE rejected Opdivo (nivolumab) in this use in a preliminary decision in April because of uncertainties in the clinical evidence, before the drug had even received its European licence.

Opdivo (nivolumab) is the frontrunner in the PD-1 class of checkpoint inhibitor drugs, a new generation of immunotherapy drugs expected to advance treatment across many different tumour types ...

BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its ...

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

Pharmac is also consulting on a joint proposal with Medsafe to increase access to ADHD medicines. The consultation is considering changes to the regulations and funding restrictions stimulant ...